Who are Multaq's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zinc Pyrithione, Katadolon, Tikosyn, Corvert, Tambocor, Mexitil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dronedarone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Multaq — Competitive Intelligence Brief

Multaq (DRONEDARONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic [EPC]. Area: Cardiovascular.

marketed Antiarrhythmic [EPC] Potassium voltage-gated channel subfamily KQT member 2 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Multaq (DRONEDARONE) — Sanofi. Multaq works by blocking abnormal electrical signals in the heart to restore a normal heartbeat.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Multaq TARGET	DRONEDARONE	Sanofi	marketed	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily KQT member 2	2009-01-01
Zinc Pyrithione	PYRITHIONE ZINC		marketed	pyrithione zinc	Potassium voltage-gated channel subfamily KQT member 2	1986-01-01
Katadolon	FLUPIRTINE		marketed	flupirtine	Serine hydroxymethyltransferase, mitochondrial, Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3
Tikosyn	DOFETILIDE	Pfizer	marketed	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily H member 2	1999-01-01
Corvert	IBUTILIDE	Pfizer	marketed	Antiarrhythmic	Potassium voltage-gated channel subfamily H member 2	1995-01-01
Tambocor	FLECAINIDE		marketed	Antiarrhythmic	Potassium voltage-gated channel subfamily H member 2	1985-01-01
Mexitil	MEXILETINE	Boehringer Ingelheim	marketed	Antiarrhythmic	5-hydroxytryptamine receptor 2B	1985-01-01

Recent regulatory actions (last 90 days)

2026-03-23 — Mexitil · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic [EPC] class)

Pfizer · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Multaq — Competitive Intelligence Brief. https://druglandscape.com/ci/dronedarone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab